First published OCT 10, 2023 Updated 46 minutes ago Auckland-based business reporter specialises in property, aged care, logistics and markets. Show more Business Difficulty securing cash needed to commercialise technology led to Avalia's liquidation The inability to get further funding has led to the shareholders of hepatitis B, cancer and Covid-19 vaccine business Avalia Immunotherapies liquidating the venture.

https://www.newsroom.co.nz/pro/funding-problems-end-another-vaccine-startup

#newsroom